Weekly systemic cisplatin plus locoregional hyperthermia: An effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area

References

• Randall ME, Michael H, Vermorken J, Stehman F. Uterine cervix. Principles and practice of gynaecologic oncology, WJ Hoskins, CA Perez, RC Young, RR Barakat, M Markham, ME Randall, et al. Williams and Wilkins, Philadelphia, Lippincott 2005; 743–822
   Google Scholar
• Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynaecologic Oncology Group study. J Clin Oncol 2004; 22: 3113–3119
   PubMed Web of Science ®Google Scholar
• Long HJ, Bundy BN, Grendys EC, Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynaecologic Onology Group Study. J Clin Oncol 2005; 23: 4626–4633
   PubMed Web of Science ®Google Scholar
• Papadimitriou CA, Sarris K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E, Dimopoulos MA. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999; 17: 761–766
   PubMed Web of Science ®Google Scholar
• Piver MS, Ghamande SA, Eltabbakh GH, O’Neill-Coppola C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix ã A phase II study. Gynecol Oncol 1999; 75: 334–337
   PubMed Web of Science ®Google Scholar
• Cadron I, Jakobsen A, Vergrote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/5-fluorouracil in recurrent cervical cancer. Gynaecol Obstet Invest 2005; 59: 126–129
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A. Phase I/II dose-finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol 2006; 103: 160–164
   PubMed Web of Science ®Google Scholar
• Reinhold HS, Endrich B. Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986; 2: 111–137
   PubMedGoogle Scholar
• Raaphorst GP. Fundamental aspects of hyperthermic biology. An introduction to the practical aspects of clinical hyperthermia, SB Field, JW Hand. Taylor and Francis, London 1990; 10–54
   Google Scholar
• Dahl O. Interaction of heat and drugs in vitro and in vivo. Thermoradiotherapy and thermochemotherapy, MH Seegenschmiedt, P Fessenden, CC Vernon. Springer, Berlin 1995; 103–121
   Google Scholar
• Rietbroek RC, van der Vaart PJM, Haveman J, Blommaert FA, Geerdink A, Bakker PJM, Veenhof CHN. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123: 6–12
   PubMed Web of Science ®Google Scholar
• de Wit R, van der Zee J, van der Burg ME, Kruit WH, Logmans A, van Rhoon GC, Verweij J. A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 1999; 80: 1387–1391
   PubMed Web of Science ®Google Scholar
• Rietbroek RC, Schilthuis MS, Bakker PJ, van Dijk JD, Postma AJ, Gonzalez GD, Bakker AJ, van der Velden J, Helmerhorst TJ, Veenhof CH. Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 1997; 79: 935–943
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996; 155: 1227–1232
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Zvi L, Baniel J, Caldarera E, Pavone-Macaluso M. Multicentric study comparing intravesical chemotherapy alone with local microwave hyperthermia for profylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21: 4270–4276
   PubMed Web of Science ®Google Scholar
• Kondo M, Itani K, Yoshikawa T, Tanaka Y, Watanabe N, Hiraoka M, Noguchi M, Miura K. A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer. Gan To Kagaku Ryoho 1995; 22: 1807–1811
   PubMedGoogle Scholar
• Sugimachi K, Kuwano H, Ide H, Toge T, Saku M, Oshiumi Y. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: A prospective randomized trial. Int J Hyperthermia 1994; 10: 485–493
   PubMed Web of Science ®Google Scholar
• Chambers SK, Flynn SD, Del Prete SA, Chambers JT, Schwartz PE. Bleomycin, vincristine, mitomycin C, and cis-platinum in gynecologic squamous cell carcinomas: A high incidence of pulmonary toxicity. Gynecol Oncol 1989; 32: 303–309
   PubMedGoogle Scholar
• Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve ALJ, de Wit R, van der Velden J, Burger C, et al. First results of triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia for treatment of patients with stage IIB, II and IVA cervical carcinoma. Cancer 2005; 104: 763–770
   PubMed Web of Science ®Google Scholar
• Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing JA. Cisplatinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. Cancer 1981; 48: 899–903
   PubMed Web of Science ®Google Scholar
• Potter ME, Hatch KD, Potter MY, Shingleton H, Baker VV. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 1989; 63: 1283–1286
   PubMed Web of Science ®Google Scholar
• Daly M, Cowie VJ, Davis JA, Habeshaw T, Junor EJ, Paul J, Pyper E, Reed M, Soukop M, Yosef H, et al. A short and intensive single-agent cisplatin regimen for recurrent carcinoma of the uterine cervix. Int J Gynaecol Cancer 1996; 6: 61–67
   Google Scholar
• de Murua EO, George M, Pejovic MH, Dewailly J, Wolff JP. Combination cyclophosphamide, adriamycin, and cis-platinum in recurrent and metastatic cervical carcinoma. Gynecologic Oncol 1987; 26: 225–227
   PubMedGoogle Scholar
• Lele SB, Piver MS. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol 1989; 33: 6–8
   PubMedGoogle Scholar
• Ramm K, et al. Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look. Gynecol Oncol 1992; 46: 203–207
   PubMedGoogle Scholar
• Brader KR, Vergrote IB, Kaern J, Tropé CG. Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design. J Clin Oncol 1998; 16: 1879–1884
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Gershenson DM, McGhee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1999; 17: 2676–2680
   PubMed Web of Science ®Google Scholar
• Burnett AF, Roman LD, Garcia AA, Muderspach LI, Brader KR, Morrow CP. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent or recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 2000; 76: 63–66
   PubMed Web of Science ®Google Scholar
• Fiorica J, Holloway R, Ndubisi B, Orr J, Grendys E, Boothby R, DeCesare S, LaPolla J, Hoffman M, Patel J. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and non-squamous carcinomas of the cervix. Gynecol Oncol 2002; 85: 89–94
   PubMed Web of Science ®Google Scholar
• Gebbia V, Caruso M, Testa A, Mauceri G, Borsellino N, Chiarenza M, Pizzardi N, Palmeri S. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix. Oncology 2002; 63: 31–37
   PubMedGoogle Scholar